Edesa Biotech, Inc. (EDSA): Nasdaq/NYSE listing notice — Edesa Biotech receives Nasdaq deficiency letter for bid price below $1, has 180 days to cure

Edesa Biotech, Inc.

Company has until Dec 19, 2023 to regain compliance by closing at $1 or more for 10 consecutive business days.
If not cured, may qualify for another 180-day period subject to meeting other Nasdaq standards and a reverse split.
Nasdaq listing remains fully effective; no immediate impact on trading of EDSA common shares.
Company will monitor bid price and consider options to regain compliance, but cannot assure success.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Edesa Biotech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

June 22, 2023, Edesa Biotech, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the closing bid price of the Company’s common shares, no par value per share (the “Common Shares”), for the last 30 consecutive business days, the Company is not in compliance with the minimum bid price requirement of $1.00 per share for continued listing, as set forth in Nasdaq Listing Rule 5550(a)(2). The Nasdaq notification has no immediate impact on the listing of the Company’s Common Shares on The Nasdaq C

View on SEC.gov

Browse all listing & compliance notices →

Edesa Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-008353

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.